ãã®èšäºãèªãããšã§åããã¡ãªãããšçµè«
çµè«ãå
ã«èšããšã
ãããã¡ãªã³ïŒå®å
šïŒå±éºããšäžèšã§å€æããã®ã¯ã§ããŸãããããã¡ãªã³ãã©ã³ãã«ã¯è£œåã«ãã£ãŠæåãç°ãªããããæåã確èªããããã§ã
äžè¬çã«ã¯ã¢ã»ãã¢ãããã§ã³ïŒã¿ã€ã¬ããŒã«ç³»ïŒã¯åºè¡ãªã¹ã¯ãäœããNSAIDsïŒã¢ã¹ããªã³ãã€ãããããœãã³ãªã©ïŒã¯åºè¡ãè¡åŸã®ç®èãã©ãã«ã«æ³šæãå¿
èŠããšããçè§£ã§åé¡ãªãããšãå€ãã§ãããã ããåžžçšè¬ãæååºè¬ã®äœµçšãåŠåš äžã»æ¢åŸçãããå Žåã¯å¿
ãäºåã«æ
åœã¯ãªããã¯ãå»åž«ã«çžè«ããŠãã ããã
ãã®èšäºãèªããšã
- ããã¡ãªã³ïŒåžè²©é®çè¬ïŒã®æåéããšèŠåãæ¹ãããã
- å»çè±æ¯ïŒã¬ãŒã¶ãŒïŒãžã®åœ±é¿ïŒåºè¡ã»ççã»è±æ¯å¹æïŒãããã
- å
·äœçãªè¬ïŒã¿ã€ã¬ããŒã«ããããœãã³ãããã¡ãªã³ãªã©ïŒããšã®å€æåºæºãããã
- ã¯ãªããã¯ãå®éã«ã©ã察å¿ããããåãåãããã³ãã¬ãåœæ¥ã®ãã§ãã¯ãªã¹ããæã«å
¥ã
1) ãŸãã¯åºæ¬ïŒããã¡ãªã³ã£ãŠäœïŒæåå¥ã®éããã·ã³ãã«ã«çè§£ããã
å»çè±æ¯åã«ãããã¡ãªã³é£²ãã§ã倧äžå€«ïŒããšäžå®ã«ãªã人ãå€ãã§ãããããŸãã¯ããã¡ãªã³ãšã¯äœããæŒãããŸãããã
1-1. ããã¡ãªã³ãšã¯ïŒ
ããã¡ãªã³ã¯æ¥æ¬ã§åºãç¥ãããåžè²©ã®é®çè¬ãã©ã³ãåã§ãããã ãæ³šæç¹ãšããŠã
ãããã¡ãªã³ããšããååã§ã補åããšã«äž»æåãç°ãªãå Žåããããããæåè¡šç€ºïŒæ·»ä»ææžãç®±ã®è£ïŒãå¿
ã確èªããŠãã ããã代衚çã«ã¯ã¢ã»ãã«ãµãªãã«é
žïŒã¢ã¹ããªã³ïŒãå«ã補åãæŽå²çã«æåã§ãããããã¡ãªã³ãã©ã³ãã§ãæåãå€ããã©ã€ã³ãããããããŸãã
1-2. åžè²©é®çè¬ã®äž»ãªæåãšç¹åŸŽïŒç°¡åã«ïŒ
- ã¢ã»ãã¢ãããã§ã³ïŒãã©ã»ã¿ã¢ãŒã«ïŒïŒåååã§ã¯ã¿ã€ã¬ããŒã«ãã«ãããŒã«ïŒåŠæ¹åïŒã«çžåœã
é®çã»è§£ç±å¹æããããè¡å°æ¿æ©èœã«å€§ããªåœ±é¿ãäžããªãããåºè¡ãªã¹ã¯ãæ¯èŒçäœãã
- NSAIDsïŒéã¹ããã€ãæ§æççè¬ïŒïŒã€ããããã§ã³ïŒã€ãïŒããããœãããã§ã³ïŒãããœãã³ïŒãã¢ã¹ããªã³ïŒã¢ã»ãã«ãµãªãã«é
žïŒãªã©ã
é®çã ãã§ãªãæççäœçšãããäžæ¹ã§ãè¡å°æ¿æ©èœãæããŠåºè¡ãããããªãå¯èœæ§ãããã
- ãã®ä»ïŒè£œåã«ãã£ãŠã¯è€åæåïŒã«ãã§ã€ã³äœµçšãªã©ïŒãæ¶ååšä¿è·æåãå«ãå ŽåããããŸãã
1-3. 代衚çãªè£œååãšæåäŸïŒå®äŸïŒ
- ã¿ã€ã¬ããŒã«ïŒã¿ã€ã¬ããŒã«AçïŒïŒã¢ã»ãã¢ãããã§ã³
- ã«ãããŒã«ïŒå»ççšåïŒïŒã¢ã»ãã¢ãããã§ã³ïŒåŠæ¹ïŒ
- ãããœãã³ïŒãããœãããã§ã³ïŒïŒåŠæ¹è¬ã ãåžè²©ã«é¡äŒŒæåãã
- ã€ãïŒã€ããããã§ã³ïŒïŒåžè²©ã®ä»£è¡šçNSAID
- ããã¡ãªã³ïŒè£œåã«ããæåãç°ãªãïŒã¢ã¹ããªã³ç³»ã»ãã®ä»ïŒ
â»å¿
ãç®±ãæ·»ä»ææžã®ãæå¹æåãæ¬ã確èªããŠãã ããã
1-4. ããããã®å¯äœçšãšæ³šæç¹ïŒãã£ããïŒ
- ã¢ã»ãã¢ãããã§ã³ïŒèæ©èœãžã®åœ±é¿ïŒééæçšã§ãªã¹ã¯ïŒãæ¯èŒçåºè¡ã¯èµ·ãã«ããã
- NSAIDsïŒèè
žé害ïŒè朰çãªã©ïŒãè
æ©èœãžã®åœ±é¿ãè¡å°æ¿æ©èœæå¶ã«ããåºè¡åŸåã®å¢å ïŒæè¡ã»åŠçœ®åã¯æ³šæïŒã
- ã¢ã¹ããªã³ïŒã¢ã»ãã«ãµãªãã«é
žïŒïŒè¡å°æ¿æå¶ã¯
äžå¯éçã§ãå¹æã¯æ°æ¥ïœ1é±éçšåºŠç¶ãããšããããããæè¡åã®äžæ¢ãæšå¥šãããå Žé¢ãããã
1-5. æåãå¿
ã確èªããæ¹æ³
- è¬ã®ç®±ãèª¬ææžïŒæ·»ä»ææžïŒã®ãæåãæ¬ãèŠã
- è¬å€åž«ã«çŽæ¥èãïŒæ¥é¢åã«è¬å±ã§çžè«ïŒ
- ã¹ããã§ã補åå æåãã§æ€çŽ¢ïŒãã ãå
Œξ
å ±ã§ããããšã確èªïŒ
ïŒãããŸã§ã§ãããã¡ãªã³ïŒäžåŸã§ã¯ãªãç¹ãæåã®éããšãããåºè¡ãªã¹ã¯ã«ã©ãé¢ä¿ããããæŒãããŸãããæ¬¡ã¯å»çè±æ¯ãšè¬ã®é¢ä¿ã§ããïŒ
2) å»çè±æ¯äžã«è¬ã飲ããšäœãèµ·ããïŒïŒå¹æã»åºè¡ã»èãã©ãã«ã®èŠç¹ïŒ
è±æ¯ã®ä»çµã¿ãšçã¿ã»å¯åå¿ã®åå ãçè§£ãããšãè¬ã®åœ±é¿ãã€ã¡ãŒãžãããããªããŸãã
2-1. å»çè±æ¯ïŒã¬ãŒã¶ãŒã»èç±åŒïŒã®ä»çµã¿ãšçã¿ã®æ£äœ
- å»çè±æ¯ã®ã¬ãŒã¶ãŒã¯æ¯æ ¹ïŒæ¯ä¹³é ïŒãæ¯å
ã®ã¡ã©ãã³ã«ãšãã«ã®ãŒãäžããŠç±ã§ç Žå£ã»æžèãããŸãã代衚çãªæ©åšã¯ã¢ã¬ããµã³ãã©ã€ãããã€ãªãŒããYAGãªã©ã
- çã¿ã¯ã¬ãŒã¶ãŒç±ã«ããç®èåºæ¿ãæ¯å
åšå²ã®ç¥çµåºæ¿ãå人差ïŒèã®åãã»æ¯éïŒã«ãã£ãŠçããŸããVIOãç·æ§ãã²ã¯çã¿ã匷ãæããããã§ãã
2-2. é®çè¬ãè±æ¯å¹æã«çŽæ¥åœ±é¿ãããïŒ
äžè¬çã«ãçæéã®é®çè¬ïŒã¢ã»ãã¢ãããã§ã³ãNSAIDsïŒã¯
ã¬ãŒã¶ãŒã®è±æ¯å¹æãã®ãã®ãçŽæ¥äžãã蚌æ ã¯å°ãªããšãããŠããŸããé®çè¬ã¯çã¿ã»ççãæããäœçšãããããã
ã¬ãŒã¶ãŒç
§å°åŸã®äžæçãªç®èåå¿ããã軜ããªãããšã¯ãã£ãŠããæ¯æ ¹ãåããã¬ãŒã¶ãŒç±ãšãã«ã®ãŒã倧ããé»å®³ããããã§ã¯ãªããšããã®ãäžè¬çèŠè§£ã§ãã
2-3. åºè¡ãªã¹ã¯ãšNSAIDsã®é¢ä¿ïŒã©ããªå Žåã«æ³šæãïŒ
- NSAIDsãã¢ã¹ããªã³ç³»ã¯è¡å°æ¿ã®åãã匱ãããããæœè¡äžãæœè¡åŸã«
åºè¡ãå
åºè¡ïŒããïŒãåºããããªãå¯èœæ§ããããŸããç¹ã«VIOãé¡ãªã©æ¯æ ¹ãç®è衚é¢è¿ãã§è¡æµã®å€ãéšäœã§ã¯ç®ç«ã€å ŽåããããŸãã
- æ¢ã«æååºè¬ïŒã¯ãŒãã¡ãªã³ãDOACãªã©ïŒã飲ãã§ããå Žåã¯ãããã«æ³šæãå¿
èŠã§ã
å¿
ãäºåã«ç³åããŠå»åž«ãšçžè«ããŠãã ããã
2-4. ççãç®èãã©ãã«ãžã®åœ±é¿ïŒæççè¬ã®åãïŒ
- æççäœçšã®ããNSAIDsã¯æœè¡åŸã®èµ€ã¿ãè
«ããæãã广ãæåŸ
ã§ããŸãããåæã«è¡æµãå
ç«åå¿ã«åœ±é¿ããå¯èœæ§ãããããã
ã¯ãªããã¯ã®æç€ºã«åŸãããšãéèŠã§ãã
- ã¢ã»ãã¢ãããã§ã³ã¯æççäœçšã匱ãäžæ¹ã§åºè¡ãªã¹ã¯ãäœããæœè¡åŸã®çã¿æ¢ããšããŠäœ¿ãããããšãå€ãã§ãã
2-5. æœè¡ååŸã«è¬ã飲ãããšã§èµ·ãããå¯äœçšã®å®äŸ
- èãèããïŒNSAIDsã空è
¹ã«é£²ããšèçãåºè¡æ§èè
žé害ãèµ·ããããšããããŸãã
- å
åºè¡ãåºãããïŒNSAIDsãã¢ã¹ããªã³äœµçšã«ããããã»åºè¡ã
- èæ©èœã«æ³šæïŒã¢ã»ãã¢ãããã§ã³ã¯ééæã«èé害ãªã¹ã¯ããïŒã¢ã«ã³ãŒã«åžžé£²è
ã¯ç¹ã«æ³šæïŒã
å®éã®ã±ãŒã¹ã§ã¯ã軜床ã®èµ€ã¿ã»è
«ãã§æžãããšãå€ãã§ãããé節ãªåºè¡ãææãçãããå Žåã¯ããã«ã¯ãªããã¯ã«é£çµ¡ããŸãããã
3) ããã¡ãªã³ã¯å»çè±æ¯ã§é£²ãã§ããïŒæåå¥ã®å
·äœç倿ã¬ã€ã
ããã§ã¯ãæåå¥ãã«ããããããå€æåºæºã瀺ããŸãããªãæçµå€æã¯æ
åœå»ã«å¿
ã確èªããŠãã ããã
3-1. ã¢ã»ãã¢ãããã§ã³ç³»ïŒã¿ã€ã¬ããŒã«ã»ã«ãããŒã«çžåœïŒïŒå©ç¹ãšæ³šæç¹
- å©ç¹ïŒ
è¡å°æ¿æ©èœã«ã»ãšãã©åœ±é¿ãäžããªããããåºè¡ãªã¹ã¯ãäœããçã¿æ¢ããšããŠåºã䜿ããããæœè¡ååŸã®çæçãªäœ¿çšã¯å€ãã®ã¯ãªããã¯ã§èš±å®¹ãããããšãå€ãã
- 泚æç¹ïŒå€§éæçšãæ
¢çšã§èæ©èœé害ã®ãªã¹ã¯ãã¢ã«ã³ãŒã«åžžé£²è
ãèçŸæ£ã®ãã人ã¯å»åž«ã«çžè«ã
ããããã®äœ¿ãæ¹ïŒäžè¬è«ïŒïŒ
- æœè¡çŽåã®æçšã¯ã¯ãªããã¯ã«ãã£ãŠæç€ºãåããããããäºåã«ç¢ºèªã
æœè¡åŸã«çã¿ãåºããã¢ã»ãã¢ãããã§ã³ã䜿ããšããæµããç¡é£ãªããšãå€ãã§ãã
3-2. NSAIDsç³»ïŒã€ããããã§ã³ããããœãããã§ã³ïŒãããœãã³ãã¢ã¹ããªã³ç³»ïŒããã¡ãªã³ã®äžéšïŒïŒå©ç¹ãšæ³šæç¹
- å©ç¹ïŒæççäœçšããããè¡åŸã«è
«ããçã¿ãæãã广ãæåŸ
ã§ããã
- 泚æç¹ïŒ
è¡å°æ¿æ©èœãæããããåºè¡ãå
åºè¡ã®ãªã¹ã¯ãäžãããã¢ã¹ããªã³ïŒã¢ã»ãã«ãµãªãã«é
žïŒã¯è¡å°æ¿æå¶ãé·åŒãïŒäžå¯éçïŒããšããããããæè¡ãå€ç§çåŠçœ®ã®åã«ã¯äžæ¢ãæç€ºãããå Žåãããã
æœè¡ååŸã®ç®å®ïŒäžè¬çãªè©±ïŒïŒ
- 軜床ã®åžè²©NSAIDsã1åã ãæçšããçšåºŠã¯å€§ããªåé¡ã«ãªããªãããšããããŸããã
æ°æ¥éé£ç¶ã§é£²ãã§ããå ŽåãåžžçšããŠããå Žåã¯èŠçžè«ã
- æœè¡åã«NSAIDsãé¿ããããæç€ºãããã¯ãªããã¯ããããŸãã
3-3. ããã¡ãªã³è£œåããšã®æåã®èŠåãæ¹ïŒå¿
ãæå衚ã確èªïŒ
- ç®±ã»æ·»ä»ææžã®ãæå¹æåãã確èªãããã«ãã¢ã»ãã«ãµãªãã«é
žãïŒïŒã¢ã¹ããªã³ïŒããã€ããããã§ã³ããã¢ã»ãã¢ãããã§ã³ããªã©ã®èšèŒãããã¯ãã§ãã
- 補ååã ãã§å€æããªãããšã
ãããã¡ãªã³Aããããã¡ãªã³EXããªã©ã§æåãéãå ŽåããããŸãã
3-4. ãæœè¡åã«é£²ããå Žåã®ç®å®ïŒäœæéåãå®å
šãïŒ
- æç¢ºãªçµ±äžã«ãŒã«ã¯ãªãã
ã¯ãªããã¯ã®æç€ºãæåªå
ãäžè¬è«ãšããŠã¯ãåºè¡ãªã¹ã¯ãäžãããå Žåã¯NSAIDsãã¢ã¹ããªã³ã®æçšãäžæ¢ïŒæ°æ¥ïœ1é±éçšåºŠãæåãåžžçšã®æç¡ã«ããç°ãªãïŒããããšãããäžæ¹ãã¢ã»ãã¢ãããã§ã³ã¯æ¯èŒçå®å
šãšãããããçŽåã®æçšã蚱容ããæœèšãå€ãã§ãã
- æœè¡åŸã®çã¿ã«åããŠäºåã«ã¢ã»ãã¢ãããã§ã³ã飲ããã©ããã¯ã¯ãªããã¯ã«çžè«ããŸãããã
3-5. åžžçšè¬ãæç
ããã人ã®å¯Ÿå¿ïŒæååºè¬ã»æ¶åæ§æœ°ççïŒ
- ã¯ãŒãã¡ãªã³ãDOACïŒæååºè¬ïŒãæçšããŠããå Žåã¯
å¿
ãç³åãè±æ¯ã¯éåºè¡æ§åŠçœ®ãå€ãã§ãããéšäœãç
§å°åŒ·åºŠã«ãã£ãŠã¯åºè¡ãå
åºè¡ã®ãªã¹ã¯ããããããå
ç§å»ãšçžè«ã®ããã§èšç»ãç«ãŠãå¿
èŠããããŸãã
- æ¶åæ§æœ°çã®æ¢åŸããã人ã¯NSAIDsãé¿ããã¹ãå Žåãããã®ã§ãã¢ã»ãã¢ãããã§ã³ã代æ¿ãšããŠææ¡ãããããšãå€ãã§ãã
4) å®éã®ã¯ãªããã¯ã¯ã©ãæ¡å
ããŠããïŒïŒå
¬åŒæ¡å
ã®æ¢ãæ¹ãšäŸïŒ
ã¯ãªããã¯ã«ãã£ãŠåŸ®åŠã«å¯Ÿå¿ã¯å€ãããŸããããã§ã¯å®äŸãšåãåããæã«äœ¿ãã質åãªã¹ãã玹ä»ããŸãã
4-1. ã¯ãªããã¯ã«ç¢ºèªããã¹ãå
·äœçãªè³ªåãªã¹ã
æ¥é¢åãäºçŽæã«ç¢ºèªãããšå®å¿ãªè³ªåïŒ
- ãçŸåšé£²ãã§ããè¬ïŒåžè²©è¬å«ãïŒã§ç³åãã¹ããã®ã¯ãããŸããïŒã
- ãããã¡ãªã³ïŒè£œååïŒãæçšããŠããã®ã§ãããæœè¡åã«äžæ¢ãå¿
èŠã§ããïŒã
- ãæååºè¬ãè¡ããµã©ãµã©ã«ããè¬ã飲ãã§ããå Žåãã©ãããã°ããã§ããïŒã
- ãæœè¡åœæ¥ã®é£²ã¿è¬ã®æ±ãïŒæã«é£²ãã»é£²ãŸãªãïŒã¯ã©ãããã°ããã§ããïŒã
4-2. 代衚ã¯ãªããã¯ã®äžè¬çãªå¯Ÿå¿äŸïŒåŸåïŒ
- æ¹åçŸå®¹ã¯ãªããã¯ïŒSBCïŒïŒæ¥é¢æã®å蚺ã§åžžçšè¬ã»æ¢åŸæŽã確èªããæååºè¬ãªã©éèŠãªè¬ã¯äºåçžè«ãä¿ããåžè²©ã®é®çè¬ã¯æåã«ããæç€ºãåãããå Žåããã
- ã¬ãžãŒãã¯ãªããã¯ïŒæœè¡åã®å蚺ã§è¬ã®ç³åãæ±ããVIOãªã©åºè¡ããããéšäœã¯ç¹ã«æ
éã«å¯Ÿå¿ã
- ãªãŒã¯ãªããã¯ïŒè¬ã®å蚺ãæç
ã®ç¢ºèªãéèŠãå¿
èŠæã¯äž»æ²»å»ãšã®é£çµ¡ãæšå¥šã
- ãŽãªã©ã¯ãªããã¯ïŒç·æ§åãïŒïŒãã²è±æ¯ãªã©çã¿ã匷ãéšäœã§ã¯éº»é
ãªãã·ã§ã³ãæç€ºãè¬ã®æçšã«ã€ããŠã¯åå¥å€æã
ïŒâ»ã¯ãªããã¯ããšã®çްããªã«ãŒã«ã¯å€ãããããå¿
ãå
¬åŒFAQãäºçŽæã«ç¢ºèªããŠãã ãããïŒ
4-3. äºçŽæã»å蚺祚ã§ç³åãã¹ãè¬ã»æ¢åŸç
- åŠæ¹è¬ïŒç¹ã«æååºè¬ãå
ç«æå¶è¬ãã¹ããã€ãïŒ
- åžè²©è¬ã®åžžçšïŒããã¡ãªã³ããããœãã³ãã€ããã¿ã€ã¬ããŒã«ãªã©ïŒ
- ãµããªã¡ã³ãïŒãã¿ãã³Eããªã¡ã¬3ãªã©äžéšã«åºè¡åŸåãå©é·ãããã®ããïŒ
- ã¢ã¬ã«ã®ãŒïŒéº»é
è¬ã¢ã¬ã«ã®ãŒå«ãïŒ
ãããã¯åèšºç¥šã«æ£ç¢ºã«èšèŒããŸãããã
4-4. ã¯ãªããã¯åŽãåŠæ¹ããé®çã»éº»é
ã®çš®é¡ïŒäŸïŒ
- ã«ãããŒã«ïŒã¢ã»ãã¢ãããã§ã³ãåŠæ¹ïŒ
- å±æéº»é
ã¯ãªãŒã ïŒãšã ã©/EmlaïŒã麻é
ããŒã
- ãã©ã ã»ããçã®é®çè¬ïŒåŒ·ãçã¿ã®å ŽåãåŠæ¹ãããããšãããïŒ
ã¯ãªããã¯ã«ãã£ãŠã¯ç¬æ°éº»é
ïŒåžå
¥éº»é
ïŒãçšæããŠãããšããããããŸãïŒäž»ã«çã¿ã匷ãéšäœãç·æ§ã®ãã²ã§æç€ºãããããšãå€ãïŒã
4-5. æœè¡åœæ¥ã®é£²é
ã»å
¥æµŽã»è¬ã®NGè¡çº
- 飲é
ïŒè¡ç®¡æ¡åŒµãšè¡æµå¢å ã«ã€ãªãããããæœè¡åœæ¥ã®å€§é飲é
ã¯é¿ããããã«æç€ºãããããšãå€ãã§ãã
- å
¥æµŽïŒç
§å°çŽåŸã¯é·æ¹¯ãç±ãã颚åã§ã®åºæ¿ãé¿ããæç€ºãäžè¬çã
- è¬ïŒæç€ºããªãéããåžžçšè¬ã¯èªå·±å€æã§äžæ¢ãããå¿
ãäºåçžè«ãåžè²©è¬ã®èªå·±å€æã§ã®äžæ¢ã»è¿œå ã¯é¿ããã
5) çã¿å¯Ÿçã®éžæè¢ãæ¯èŒïŒè¬ä»¥å€ã®å¯ŸåŠãå«ããŠ
è¬ä»¥å€ã«ãçã¿ãäžããææ®µã¯ãããããããŸããçµã¿åãããŠäœ¿ããšå¹æçã§ãã
5-1. å±æéº»é
ã¯ãªãŒã ïŒãšã ã©/EmlaïŒã®å¹æãšäœ¿ãæ¹
- ãšã ã©ã¯ãªãã«ã€ã³ãšããªãã«ã€ã³ã®æ··åã¯ãªãŒã ã§ãç®èã®è¡šé¢éº»é
ã«æå¹ã
å¡åžããŠãã30ïœ60åã§å¹æãåºãããšãå€ããã¯ãªããã¯ã§æ¡çšããŠããå Žåã¯äºåã«å¡åžããŠããããããèªå·±å¡åžã®æç€ºãããã確èªããŸãããã
- 泚æïŒæ·±éšã®çã¿ãŸã§ã¯å®å
šã«åããªãããšããããé¡ãVIOã§ã¯å¹æã®å人差ããã
5-2. å·åŽãžã§ã«ã»ã¢ã€ã¹ããã¯ã®åœ¹å²
- ç
§å°äžãç
§å°çŽåŸã®å·åŽã¯çã¿è»œæžãšç®èä¿è·ã«éèŠãå·åŽã匷åããŠããå»çæ©åšããããŸããèªå®
ã§ã®ã¢ã€ã·ã³ã°ã¯ãããããããšåå·ã®ãªã¹ã¯ãããã®ã§çæéïŒæ°åïŒã«çããã
5-3. åŒåžæ³ããªã©ãã¯ã¹æ³ã§çã¿ãåããããã¯ããã¯
- æ·±åŒåžã»è
¹åŒåŒåžã声ãåºãïŒè»œããããïŒãšçã¿ã®æèŠãåããããšããããŸããç·åŒµã匷ããšçã¿ãæããããã®ã§ããªã©ãã¯ã¹æ³ã¯æå€ãšæå¹ã§ãã
5-4. äºåã®ã·ã§ãŒãã³ã°ã»ä¿æ¹¿ã§çã¿ã軜ãããæ¹æ³
- æå®ã®æ¹æ³ã§ã®èªå·±ã·ã§ãŒãã³ã°ïŒæ¯ãé·ããšç±ã忣ãçã¿å¢ïŒãã也ç¥ãé²ãããã®ä¿æ¹¿ã¯æœè¡ã®ãããããšçã¿è»œæžã«ã€ãªãããŸããã¯ãªããã¯ã®æç€ºã«åŸããŸãããã
5-5. ã©ãããŠãçãå Žåã®è¿œå ãªãã·ã§ã³ïŒéº»é
ããŒãã»ç¬æ°éº»é
ãªã©ïŒ
- 麻é
ããŒãïŒå±æé®çïŒãç¬æ°éº»é
ïŒåžå
¥é®éïŒã¯äžéšã®ã¯ãªããã¯ã§æäŸãç·æ§ã®ãã²ãVIOãªã©çã¿ã®åŒ·ãéšäœã§äœ¿ãããããšãå€ãã§ããè²»çšãå®å
šæ§ïŒå¯äœçšïŒãäºåã«ç¢ºèªã
6) å
·äœçãªè¬ã®ååã§èšããšïŒïŒåžè²©è¬ã»åŠæ¹è¬ã®ãããããšæ³šæïŒ
ããã§ã¯åååããŒã¹ã§æŽçããŸãããããŸã§äžè¬çãªæ
å ±ã§ãã
6-1. ã¢ã»ãã¢ãããã§ã³ç³»ïŒã¿ã€ã¬ããŒã«ãã«ãããŒã«ïŒïŒç¹åŸŽãšäœ¿ãã©ãã
- ç¹åŸŽïŒåºè¡ãªã¹ã¯ãäœããèèã«è² æ
ããããå¯èœæ§ãããã
- 䜿ãã©ããïŒæœè¡åœæ¥ã®çã¿æ¢ããšããŠå€ãã®ã¯ãªããã¯ã§æšå¥šãããããšãããã
ã¢ã«ã³ãŒã«å€é£²ãèçŸæ£ãããå Žåã¯æçšåã«å»åž«ã«çžè«ã
6-2. ãããœãã³ïŒãããœãããã§ã³ïŒãã€ãïŒã€ããããã§ã³ïŒïŒç¹åŸŽãšãªã¹ã¯
- ç¹åŸŽïŒé®çã»æçç广ã匷ãããã ãèè
žé害ãåºè¡ãªã¹ã¯ã«æ³šæã
- 䜿ãã©ããïŒè¡åŸã®ççãæããç®çã§åŠæ¹ãããããšã¯ãããŸããã
æœè¡åã«èªå·±å€æã§ç¶ç¶ããŠé£²ãã®ã¯é¿ããã¯ãªããã¯ã«ç¢ºèªã
6-3. ããã¡ãªã³ã®ä»£è¡šç補åãšæ³šæç¹
- 補ååã«ãã£ãŠã¯ã¢ã¹ããªã³ïŒã¢ã»ãã«ãµãªãã«é
žïŒãå«ããã®ããããŸãã
ã¢ã¹ããªã³ã¯è¡å°æ¿æ©èœãé·æéæãããããæè¡åã®äžæ¢ãå¿
èŠãšãªãå Žåãããã補åããšã«æåã確èªããŠãã ããã
6-4. 挢æ¹ããµããªã¯ã©ããïŒïŒé®ç广ãšå®å
šæ§ã®èгç¹ïŒ
- äžéšã®æŒ¢æ¹ããµããªïŒäŸïŒã€ããã³ã°ããªã ããŒãºããªã¡ã¬3ãé«çšéãã¿ãã³EçïŒã¯è¡æ¶²ååºã«åœ±é¿ããå¯èœæ§ãããã
è±æ¯ã®ååŸã¯æ³šæãèªå·±å€æã§ã®äžæ¢ã»éå§ã¯é¿ããå»åž«ã«çžè«ã
6-5. åŠåš äžã»æä¹³äžã«äœ¿ããè¬ãšé¿ããã¹ãè¬
- åŠåš äžïŒå€ãã®NSAIDsïŒç¹ã«åŠåš åŸæïŒã¯èå
ãåºç£ã«åœ±é¿ããããé¿ããã¹ããäžæ¹ã§ã¢ã»ãã¢ãããã§ã³ã¯å»åž«ã®æç€ºã®ããšã§äœ¿ãããããšããããŸããã
å¿
ãç£ç§å»ã«çžè«ããŠãã ãããæä¹³äžãè¬ã®éžæã¯æ
éã«ã
7) ã±ãŒã¹å¥ã®å
·äœçãªå¯ŸåŠæ³ïŒãã«ãœãå¥ã®Q&AïŒ
ãã«ãœãã«åãããå®è·µçãããŒãæç€ºããŸãã
7-1. åããŠã®å»çè±æ¯ã§ããã¡ãªã³ã飲ã¿ããåŠçã®å Žå
ãããŒïŒ
1. æçšãããããã¡ãªã³ã®ç®±ãçšæããŠæåã確èªã
2. äºçŽæãŸãã¯å蚺祚ã«ãåžè²©è¬ïŒè£œååïŒãæçšããŠããããšèšèŒã
3. æ¥é¢åã«ã¯ãªããã¯ãžãæœè¡åã«1åæçšããŠãããïŒããšç¢ºèªã
å€ãã®å Žåã
ã¢ã»ãã¢ãããã§ã³å«æã®è£œåãªã倧ããªåé¡ã¯å°ãªãããã¢ã¹ããªã³å«æãªãäžæ¢ãæç€ºãããããšãããã®ã§èŠæ³šæã
7-2. é çã§åžžçšãã人ïŒããã¡ãªã³åžžçšïŒã®è±æ¯ååŸã®æ³šæ
- åžžçšããŠããè¬ã¯å蚺ã§å¿
ãç³åã
åžžçšéããããªãäžæ¢ããã®ããªã¹ã¯ããããããå
ç§ã䞻治å»ãšçžè«ãè±æ¯èšç»ã調æŽããŸããå¿
èŠãªã代æ¿ã®é®çæç€ºãåããã
7-3. æååºè¬ïŒã¯ãŒãã¡ãªã³çïŒã飲ãã§ãã人ã®å蚺åãã§ãã¯ãªã¹ã
- å
æããŠããè¬åã»çšéã»äž»æ²»å»ã®é£çµ¡å
ãæºå
- å
ç§ã»åŸªç°åšå
ç§ã®æç€ºãä»°ããè±æ¯ãåããããããè¬ã®äžæäžæãå¿
èŠãæ€èš
- ã¯ãªããã¯åŽãšäºå®ãããåããããªã¹ã¯ãå
±æ
7-4. åŠåš äžã»æä¹³äžã®äººãè±æ¯ãåããéã®è¬ã®æ±ã
- åŠåš äžã¯å€ãã®ã¯ãªããã¯ãè±æ¯èªäœãæšå¥šããªãã»æ
éã«è¡ãæ¹éãããããããŸãã¯ç£ç§å»ãšçžè«ãè¬ã¯å¿
ãå»åž«ã®æç€ºã«åŸã£ãŠãã ãããæä¹³äžãè¬ã®éžæã¯æ
éã«ã
7-5. ææèãã¢ã¬ã«ã®ãŒæ¢åŸããã人ãåãã¹ã远å ã®å®å
šç
- ããããã¹ãã®å®æœãäŸé ŒïŒå€ãã®ã¯ãªããã¯ã§å¯èœïŒ
- 麻é
ã¯ãªãŒã ãåŠæ¹è¬ã«å¯Ÿããã¢ã¬ã«ã®ãŒæŽãå蚺ã§ç³å
- æœè¡åŸã®ä¿æ¹¿ãšçç管çã®æç€ºãäºåã«èããŠãã
8) äœéšè«ã»ç§èŠïŒå®äœéšïŒå人çãªããããïŒ
ããã¯ç§ïŒçè
ïŒã®å®äœéšãšæ£çŽãªææ³ã§ããå人çãªäœéšãªã®ã§åèçšåºŠã«ã©ããã
8-1. ç§ãå»çè±æ¯ãåããæã«è©Šããçã¿å¯Ÿç
ç§ã¯VIOãšãã¶äžã®è±æ¯ãåããçµéšããããŸããæœè¡ã§ã¯
ãšã ã©ïŒå±æéº»é
ã¯ãªãŒã ïŒãå¡ã£ãŠããããç
§å°äžã¯å·åŽãååã§æã£ãããèããããŸãããçã¿ãæ°ã«ãªãéšäœã¯ç¬æ°éº»é
ã麻é
ããŒããæ€èšãããšè¯ããšæããŸããã
8-2. ããã¡ãªã³ã䜿ã£ãçµéšïŒãã€é£²ãã ãã»å¹æã¯ã©ãã ã£ãã
ç§èªèº«ã¯æœè¡çŽåã«ã¯è¬ã飲ãŸãã
æœè¡åŸã«ã¢ã»ãã¢ãããã§ã³ïŒåååã«é¡ãããã®ïŒã䜿ã£ãããšããããŸããçã¿ã¯æ°æéã§æ²»ãŸããå
åºè¡ãªã©ã®åé¡ã¯ãããŸããã§ããããã ããããã¯å人ã®äœéšã«ãããŸããã
8-3. ã¯ãªããã¯ã§å§ããããæ¹æ³ïŒãšã ã©å¡åžïŒå·åŽïŒã®ææ³
ãšã ã©ã¯äžå®ã®å¹æããããŸããããVIOã®æ·±ãçã¿ãã¹ãŠãæ¶ãããã§ã¯ãããŸããã§ããã
å·åŽãšæ·±åŒåžã䜵çšããã ãã§ãçã¿ãããªãåãããŸããã¹ã¿ããã®å£°æããç
§å°éã®äŒæ©ãã¡ã³ã¿ã«é¢ã§å©ãããŸããã
8-4. å人çã«ããããããããã£ãŠããã£ãã察çããã3
1. äºåã«æåã確èªããäžã§ãå¿
èŠãªãã¢ã»ãã¢ãããã§ã³ãæºåããïŒã¯ãªããã¯ãšçžè«ïŒ
2. ãšã ã©ã麻é
ããŒãã®å©çšïŒæéãšå¹æã確èªïŒ
3. åŒåžæ³ãšå·åŽãæèããïŒã·ã³ãã«ã ãã©å¹æããïŒ
8-5. éã«ãããªãã»ããããã£ãããš
- èªå·±å€æã§NSAIDsãç¶ç¶ããŠé£²ã¿ç¶ããããšïŒæœè¡åœæ¥åèšºã§ææãããåŸãã確èªããŠäžæ¢ãæ€èšããïŒã
- 飲é
çŽåŸã«æœè¡ãåããããšïŒèµ€ã¿ãè
«ãããã匷ãåºãçµéšããïŒããããã¯åçç¹ã§ãã
9) ãããã質åïŒFAQïŒ
å
žåçãªçåã«çãçããŸãã
9-1. QïŒæœè¡çŽåã«é çãâŠä»ãã飲ãã§ãããïŒ
AïŒ
ãŸãã¯ã¯ãªããã¯ã«é»è©±ã§ç¢ºèªããå€ãã®å Žåãã¢ã»ãã¢ãããã§ã³ã§ããã°åé¡ãªããšèšãããããšãå€ãã§ããã補åãã¯ãªããã¯ã®æ¹éã§ç°ãªããŸãã
9-2. QïŒããã¡ãªã³ãåžžã«é£²ãã§ãããšè±æ¯ã¯åããããªãïŒ
AïŒåžžçšè¬ã¯ç³åå¿
é ã§ãããå€ãã®å Žåã¯åããããŸãããã ããæååºè¬ãªã©ç¹å®ã®è¬ã¯å¥é察å¿ãå¿
èŠã§ãã䞻治å»ãšé£æºããŠèšç»ãç«ãŠãŸãããã
9-3. QïŒãããœãã³ãšããã¡ãªã³ãã©ã¡ããè¯ãïŒ
AïŒæåã«ãããŸãããããœãã³ïŒãããœãããã§ã³ïŒã¯NSAIDã§
åºè¡ãªã¹ã¯ãäžããå¯èœæ§ããããããæœè¡åã®å€æã¯ã¯ãªããã¯ã«ç¢ºèªãããã¡ãªã³ã補åã«ããæåãç°ãªãã®ã§åæ§ã«æå確èªãã
9-4. QïŒéº»é
ã¯ãªãŒã ãå¡ã£ããè¬ã¯å¿
èŠãªãïŒ
AïŒéº»é
ã¯ãªãŒã ã§ååãªå ŽåããããŸããã广ã®å人差ããããŸããçã¿ã匷ãéšäœã¯äœµçšã远å ã®é®çãæ€èšããããšãããã®ã§ã
ã¯ãªããã¯ãšçžè«ããŸãããã
9-5. QïŒäžãäžãã©ãã«ãèµ·ãããã©ã察å¿ããïŒ
AïŒåºè¡ãææã匷ãè
«ãã»æ¿çãåºãã
éããã«æœè¡ã¯ãªããã¯ã«é£çµ¡ãå¿
èŠãããã°å蚺æç€ºãåºãŸããç·æ¥æ§ãé«ãå Žåã¯ææ¥å€æ¥åèšºãæ€èšã
10) ãŸãšãïŒå
·äœçã¢ã¯ã·ã§ã³ïŒã¯ãªããã¯äºçŽåã«ããããšãªã¹ãïŒ
æåŸã«è¡åã«ç§»ãããã§ãã¯ãªã¹ãã眮ããŸãã
10-1. ãã®èšäºã®éèŠãã€ã³ãã®çããŸãšã
- ããã¡ãªã³ã¯è£œåã«ãã£ãŠæåãç°ãªãã®ã§æå衚瀺ã確èªã
- ã¢ã»ãã¢ãããã§ã³ç³»ã¯åºè¡ãªã¹ã¯ãäœãã§æœè¡ååŸã«äœ¿ãããããšãå€ãã
- NSAIDsïŒã¢ã¹ããªã³ããããœãã³ãã€ãïŒã¯åºè¡ãªã¹ã¯ãèè
žé害ã®å¯èœæ§ããããããåžžçšã»æœè¡åã¯èŠçžè«ã
- æååºè¬ãåŠåš äžã¯å¿
ãå»åž«ã«çžè«ã
10-2. äºçŽåã«ç¢ºèªãã¹ã5ã€ã®é
ç®ïŒãã§ãã¯ãªã¹ãïŒ
1. åžžçšè¬ïŒåŠæ¹è¬ã»åžè²©è¬ã»ãµããªïŒããªã¹ãã¢ããããã
2. ããã¡ãªã³çã飲ãã§ããå Žåã¯
補ååãšæåã確èªã
3. åŠåš ã»æä¹³ã®æç¡ã確èªããå¿
èŠãªãç£ç§å»ã«çžè«ã
4. æœè¡éšäœïŒVIOãé¡ãªã©ïŒãšçã¿ã®æžå¿µãã¯ãªããã¯ã«äŒããã
5. 麻é
ãªãã·ã§ã³ãçã¿å¯Ÿçã®è²»çšãäºåã«ç¢ºèªã
10-3. åœæ¥ããã¹ãããšãªã¹ãïŒé£²é£ã»è¬ã®é£²ã¿æ¹ã»æè£
ïŒ
- æè£
ïŒç
§å°ããããæïŒVIOãèãªã©ã¯è±ãããããã®ïŒ
- 飲é£ïŒå€§éã®é£²é
ã¯é¿ãããé£äºã¯æ®æ®µéãã§OKã ããè¬ã®æçšæç€ºã¯å®ãã
- è¬ïŒã¯ãªããã¯ã®æç€ºããªããã°åžžçšè¬ã¯äžæ¢ããªãïŒåæã«æ¢ããªãïŒãåžè²©è¬ã¯æ¥é¢åã«ç¢ºèªã
- é£çµ¡å
ïŒåžžçšè¬ã®æ
å ±ã䞻治å»ã®é£çµ¡å
ãã¡ã¢ããŠããã
10-4. ã¯ãªããã¯ãžã®åãåãããã³ãã¬ïŒã³ããã§äœ¿ããæäŸïŒ
ãäºçŽãæ€èšããŠããâ¯â¯ãšç³ããŸããçŸåšâ¯â¯ïŒè¬åïŒäŸ ããã¡ãªã³ââïŒãåžžçšããŠããŸããæåã¯â¯â¯ã§ãïŒç®±ã«èšèŒã®æåãæèšïŒãå»çè±æ¯ïŒéšäœïŒäŸ VIOïŒãåãããã®ã§ãããæ¥é¢åã«äžæ¢ãå¿
èŠããå蚺å¯èœããã確èªããã ããŸããïŒã
10-5. æåŸã«ïŒå®å
šã«è±æ¯ãåããããã®å¿åŸãšçžè«å
- äžçªå€§åãªã®ã¯
äºåã®ç³åãšæ
åœå»åž«ãšã®çžè«ã§ããèªå·±å€æã§è¬ãäžæ¢ãããåžžçšè¬ã倿Žããã®ã¯é¿ããçåãããã°å¿
ãã¯ãªããã¯ã䞻治å»ã«ç¢ºèªããŠãã ãããå®å
šç¬¬äžã§èšç»ãç«ãŠããšå®å¿ããŠè±æ¯ãé²ããããŸãã
ãã®èšäºã®ãŸãšã
- ããã¡ãªã³ã¯è£œåããšã«æåãç°ãªããããæå衚ãå¿
ã確èªããããšã
- ã¢ã»ãã¢ãããã§ã³ç³»ã¯åºè¡ãªã¹ã¯ãäœããæœè¡åŸã®é®çã«äœ¿ããããã
- NSAIDsã»ã¢ã¹ããªã³ç³»ã¯åºè¡ãªã¹ã¯ãèè
žé害ã®å¯èœæ§ããããããæœè¡åã¯åå¥å€æã
- åžžçšè¬ãåŠåš ã»æååºè¬ãããå Žåã¯å¿
ã䞻治å»ãšã¯ãªããã¯ã«çžè«ããã
- çã¿å¯Ÿçã¯è¬ä»¥å€ïŒå±æéº»é
ã¯ãªãŒã ã»å·åŽã»åŒåžæ³ïŒãæå¹ãèªåã«åã£ãçµã¿åãããã¯ãªããã¯ãšçžè«ããŠæ±ºããŸãããã
ãŽãªã©ã¯ãªããã¯ è±æ¯ å€çšè¬ã¬ã€ãïœéº»é
ã¯ãªãŒã ããã¢ãã¿ãŒã±ã¢ãŸã§å
·äœåãšäœ¿ãæ¹
åºå
žã»åè
ã»å»è¬åå»çæ©åšç·åæ©æ§ïŒPMDAïŒ æ·»ä»ææžæ
å ±ããã³å»è¬åæ
å ±
ã»åçåŽåçã»è¬å€åž«åãã¬ã€ãã©ã€ã³ã«é¢ããå
¬çæ
å ±
ã»åã¯ãªããã¯ã®å
¬åŒFAQïŒæ¹åçŸå®¹ã¯ãªããã¯ãã¬ãžãŒãã¯ãªããã¯ããªãŒã¯ãªããã¯ããŽãªã©ã¯ãªããã¯ïŒ
ã»äžè¬çãªè¬çåŠã®ç¥èŠïŒã¢ã»ãã¢ãããã§ã³ãšNSAIDsã®æ¯èŒãå®å
šæ§ã«é¢ããå»çæ
å ±ïŒ
ã»åžè²©è¬ã®æå衚瀺ïŒè£œåããã±ãŒãžã»æ·»ä»ææžã«åºã¥ãç¢ºèªæ
å ±ïŒ
ïŒäžèšåºå
žã¯æ
å ±ã®ä¿¡é Œæ§ãé«ããããã®ä»£è¡šçãªæ
å ±æºã§ããææ°ã®è©³çްã¯åå
¬åŒããŒãžã»äž»æ²»å»ã«ãŠã確èªãã ãããïŒ